<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03009396</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-104-04</org_study_id>
    <nct_id>NCT03009396</nct_id>
  </id_info>
  <brief_title>Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease</brief_title>
  <acronym>MAPUS2</acronym>
  <official_title>An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label extension to the RHB-104-01 Study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label Phase III Study to Assess the Efficacy and Safety of Fixed-Dose Combination
      RHB-104 in Subjects with Active Crohn's Disease Despite 26 Weeks of Participation in the MAP
      US RHB-104-01 Study.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 18, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>16 weeks</time_frame>
    <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to remission</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>The time (weeks after randomization) that a subject first records a state of remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>The time that a subject is in a state of remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Remission</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Remission in a subject from week 16 through week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>The time that a subject is in a state of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>The time (weeks after randomization) that a subject first records a state of response.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MAP Detection at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportion of subjects with a MAP positive blood PCR assay at baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in MAP blood status</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Changes in MAP blood status by polymerase chain reaction (PCR)</description>
  </other_outcome>
  <other_outcome>
    <measure>CDEIS Changes in Those Subjects Who Undergo Colonoscopy</measure>
    <time_frame>16 and 52 weeks</time_frame>
    <description>Change from baseline in the mean Crohn's Disease Endoscopic Index of Severity (CDEIS) after 16 and 52 weeks of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>SES-CD Changes in Those Subjects Who Undergo Colonoscopy</measure>
    <time_frame>16 and 52 weeks</time_frame>
    <description>Change from baseline in the mean Simple Endoscopic Activity Score (SES-CD) after 16 and 52 weeks of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>CDEIS and SES-CD comparison in Those Subjects Who Undergo Colonoscopy</measure>
    <time_frame>52 weeks</time_frame>
    <description>Success rates of (∆CDEIS and SES-CD) defined by 25% and 50% improvements</description>
  </other_outcome>
  <other_outcome>
    <measure>CDEIS and SES-CD correlation among those Subjects Who Undergo Colonoscopy</measure>
    <time_frame>16 and 52 weeks</time_frame>
    <description>Correlation between the change from baseline in the endoscopic index (∆SES-CD) and the clinical index (∆CDAI) after 16 and 52 weeks of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Endoscopic Changes in Those Subjects Who Undergo Colonoscopy</measure>
    <time_frame>52 weeks</time_frame>
    <description>Comparison of success rates of (∆CDEIS) defined by 25% and by 50% improvements in SES-CD vs CDAI defined response</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Inflammatory Bowel Disease Quality of Life</measure>
    <time_frame>16, 26 and 52 weeks</time_frame>
    <description>Change in Inflammatory Bowel Disease Questionnaire (IBDQ) and Short Form 36 (SF-36)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in inflammatory markers</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Changes from baseline in a serum markers of inflammation: C-reactive Protein (CRP) and fecal calprotectin</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Active therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-104</intervention_name>
    <description>RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
    <arm_group_label>Active therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed fully informed consent provided as per this protocol.

          -  Participation in RHB-104-01 for 26 weeks, and a Crohn's Disease Activity Index (CDAI)
             score of ≥ 150 at Visit Week 26.

        OR

          -  More than 26 weeks, with a CDAI ≥150 at Visit Week 26 and all subsequent visits, and
             subject is between Week 26 and 52 within 4 weeks (28 days) of site activation (e.g.
             Subject with CDAI = 249 at week 26 and who is at week 38 at the time of site's
             activation for RHB-104-04 has a 4-week window to be enrolled in the open label study
             via the Optional Screening Visit)

          -  Current treatment with at least one of the following therapies which may be
             discontinued by the investigator as clinically indicated after 8 weeks of open label
             RHB-104 treatment:

               -  Oral 5-acetyl salicylic acid (5-ASA) compounds

               -  Azathioprine or 6-mercaptopurine (6-MP) or methotrexate

               -  Infliximab or adalimumab OR Current treatment with corticosteroid therapy which
                  must begin tapering after 4 weeks of treatment with open label RHB-104 (Refer to
                  Appendix 13)

          -  White blood cell count ≥ 3.5x109 at screening (RHB-104-01 Visit Week 26 visit or
             Optional Screening visit)

          -  Subject agrees to use the following effective contraceptive methods

               -  diaphragm, cervical cap, contraceptive sponge or condom) with spermicidal
                  foam/gel/cream/suppository

               -  IUD (intrauterine device) /IUS (intrauterine system)

               -  progestogen injection (Depo-Provera®) throughout the study and for at least 6
                  weeks after last study drug administration, unless subject or partner of subject
                  is post-menopausal or otherwise incapable of becoming pregnant by reason of
                  surgery or tubal ligation, or has had a vasectomy. Post-menopausal is defined as
                  having experienced 12 consecutive months without menstruation.

        In regions where local regulatory contraceptive requirements differ, the ICF (Informed
        Consent Form) will reflect local policies.

        Exclusion Criteria:

          1. Positive stool results for C. difficile.

          2. Currently diagnosed or history of uveitis confirmed by either an ophthalmologist or
             optometrist.

          3. Treatment with any medication that causes QT prolongation or Torsades de Pointes,
             including but not limited to: amiodarone, amitriptyline, astemizole, cisapride,
             citalopram dose greater than 20 mg/day, dihydroergotamine, disopyramide, dofetilide,
             dronedarone, ergotamine, ibutilide, ondansetron or other 5-HT3 (5-hydroxytryptamine)
             receptor antagonists, pimozide, procainamide, quinidine, quinine, quinolones,
             ranolazine, risperidone, sotalol, terfenadine and tolterodine. QT prolonging drugs may
             be referenced at the CredibleMeds® web site:
             https://crediblemeds.org/index.php/drugsearch/

          4. Treatment with the following CYP3A4 interactive medications: alfentanyl, alprazolam,
             amlodipine, anti-retroviral agents, apixaban, aprepitant, aripiprazole, atorvastatin,
             boceprevir, buspirone, carbamazepine, carvedilol, colchicine, cyclosporine, digoxin,
             diltiazem, estrogens, felodipine, fluconazole, fluvoxamine, grapefruit juice,
             haloperidol, ketoconazole, lovastatin, lurasidone, metoprolol, nefazodone, nifedipine,
             nisoldipine, nitrendipine, propranol, roflumilast, simvastatin, St. John's wort, and
             voriconazole.

          5. Any evidence of any newly diagnosed significant hematological, hepatic, renal,
             cardiac, pulmonary, metabolic, neurological, psychiatric or other disease (e.g.
             porphyria) that might interfere with subject's ability to safely enter and or complete
             the study requirements.

          6. Females who have a positive pregnancy test or are lactating.

          7. Refusal to sign the study informed consent form.

          8. Inability to be able to adequately communicate with the investigator or their
             respective designee and/or comply with the requirements of the entire study.

          9. Clinically significant abnormalities of hematology or biochemistry as confirmed by
             repeat testing based on investigator's discretion, including but not limited to,
             elevations greater than 2 times the upper limit of normal of Aspartate
             Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) or
             creatinine clearance less than 60 ml/min at screening via estimated Cockcroft-Gault
             formula:

             Creatinine Clearance = [140 - age in years] * weight (kg) / 72 * Serum Creatinine
             (mg/dl) [multiply estimated rate by 0.85 for women], using actual body weight.

         10. QTcF (shortening of the QT interval in the heart rate) &gt;450ms in males and QTcF&gt;460ms
             in females, bundle branch block, or major ST or T wave abnormalities that make the
             assessment of the QT impossible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira N Kalfus, MD</last_name>
    <role>Study Director</role>
    <affiliation>RedHill Biopharma Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Y Graham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine / Gastroenterology, Baylor College of Medicine, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Care Associates, Inc., 1000 Laurel Street</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia PC 711 Canton Rd. #300</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center, 720 SW Lane St.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Clinical Research, 5550 Friendship Blvd.</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies, 189 Quincy St.</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302-2926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch 6035 Shallowford Road Suite 109</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services Ltd., 601 A Discovery St.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ha'Emek Medical Center, Institute of Gastroenterology and Liver diseases, 21 Yitshak Rabin Boulevard</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Institute, Division of Medicine, Hadassah - Hebrew University Medical Center POB 12000</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medial Center, 59 Tchemacovsky St.</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital, 2 Riccarton Rd.</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>80011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital, Department of Gastroenterology, Level B1, Menzies Building, Pembroke Street</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczne Centrum Gastrologii GASTROMED, Wiejska 81</name>
      <address>
        <city>Białystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej MSW W Gdańsku Oddział Gastroenterologiczny, Ul. Kartuska 4/6</name>
      <address>
        <city>Gdansk</city>
        <zip>80-104</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNICARDIA Specjalistyczne Centrum Leczenia Chorob Serca i Naczyn &amp; UNIMEDICA. Specjalistyczne Centrum Medyczne Sp. z o.o., Kluczborska 15</name>
      <address>
        <city>Kraków</city>
        <zip>31-271</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Kliniczny w Olsztynie Oddzial Gastroenterologiczny, Zolnierska 18</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EuroMedis sp. z.o.o., Al. Powstancow Wielkopolskich 33a</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSW w Warszawie. Klinika Chorob Wewnetrznych i Gastroenterologii, Woloska 137,</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARS MEDICA s.c., Powstancow Slaskich 56A/2</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Department of Gastroenterology and Hepatology Clinic for Internal Diseases Clinical Hospital Center Zvezdara Dimitrija Tucovica 161</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Clinical Hospital Center Zemun, Vukova 9</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Gastroenterohepatology, Clinic for Internal Medicine, Clinical Center Kragujevac, Zmaj Jovina 30</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.redhillbio.com</url>
    <description>RedHill home page</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease,</keyword>
  <keyword>moderate to severe</keyword>
  <keyword>remission</keyword>
  <keyword>Mycobacterium avium paratuberculosis</keyword>
  <keyword>antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
    <mesh_term>Paratuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

